The first approach includes the elimination of TAM and monocyte accrual to the tumor site through the inhibition of mainly CSF-1/CSF-1R (Colony Stimulating Factor 1/ Colony Stimulating Factor 1 Receptor) and CCL2/CCR2 (C-C Motif Chemokine Ligand 2/ C-C Motif Chemokine Receptor 2) signaling axes. The gene discussed is CSF1; the disease is neoplasm.